Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biodistribution of 89Zr-GSK2398852 in ATTR-CM
NCT03417830Phase 1Terminated
- Sponsor
- GSK
- Start
- Apr 2018
- Primary completion
- Jul 2018
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of dezamizumab in transthyretin amyloid cardiomyopathy (ATTR-CM) (2 arms), sponsored by GSK. Primary endpoints: Peak Standardized Uptake Values (SUV) in Focal Anatomical Regions of the Heart and Mean Standardized Uptake Values (SUV) of Whole Heart. Started Apr 2018; status: terminated.
02
Drugs
dezamizumab
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT03417830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03417830.